Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1

Conditions

Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 3von Hippel-Lindau Disease 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Multiple Endocrine Neoplasia Type 1 1Multiple Endocrine Neoplasia 1Kidney Neoplasms 1Hypoglycemia 1Hypertension 1Hyperparathyroidism 1Hypercalcemia 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

gallium Ga 68 dotatate 2tanespimycin 1Vorinostat 1Ranibizumab 1Oxygen-15 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × von Hippel-Lindau Disease × gallium Ga 68 dotatate × Clear all
NCT04074135 2026-04-20

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
740 enrolled
EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT01967537 2019-11-19

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
341 enrolled 14 charts
EndocrineNET

von Hippel-Lindau Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡